Guess the Share Price One Year From Now, November 15, 2022
MrMainStreet will be tracking the results but to make his life easier, please reply only to this post with your guess so that he could easily track all submissions.
If you think there will be a buyout before November 15, 2022, submit the share price of what you think that buyout share price will be. We won't deal with CVRs, as they will complicate things.
"Mesoblast (NASDAQ:MESO) announces results from the Phase 3 trial of rexlemestrocel-L in 565 patients with New York Heart Association (NYHA) class II and class III chronic heart failure (CHF) with reduced ejection fraction (HFrEF) at the American Heart Association (AHA) annual Scientific Sessions. The new results showed a significant relationship between presence of systemic inflammation as quantified by high-sensitivity C-reactive protein (hs-CRP) and treatment benefit with rexlemestrocel-L on risk of cardiovascular mortality, heart attacks or strokes. Key findings were as follows: A single dose of rexlemestrocel-L on top of standard of care reduced the incidence of heart attacks or strokes by 65% compared with standard of care alone, p=0.001. Across 301 NYHA class II and III treated patients with high levels of inflammation (hs-CRP = 2mg/L), rexlemestrocel-L reduced the incidence of heart attacks or strokes by 79% compared with standard of care alone, p<0.001. Compared with standard of care alone, rexlemestrocel-L on top of standard of care reduced the incidence of cardiovascular death, heart attacks or strokes by 33% across all 537 NYHA class II or class III patients, p=0.02, and by 45% in the 301 patients with hs-CRP = 2mg/L, p=0.012. However, addition of rexlemestrocel-L did not further reduce the frequency of hospitalization for worsening HF symptoms as previously reported. Now Read: Mesoblast EPS beats by $0.38"
Market Data 
Markets 
AI
